Gemphire Therapeutics (GEMP) Starts Presentation at LD Micro Main Event
Gemphire Therapeutics (NASDAQ: GEMP) is a clinical-stage biopharmaceutical company focusing on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease. The company's leading product candidate is Gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. For more information, visit the company's website at www.gemphire.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned…